Review Article
Application of NAD+-Dependent Electrochemical Dehydrogenase Biosensors in Human Physiological Fluids: Opportunities and Challenges
Table 1
Enzyme immobilization schemes and analytical performance of electrochemical dehydrogenase sensors in human physiological fluids.
| Sensing scheme | Target | Limit of detection | Linear range | Response time | Storage stability (days) | Sample | Immobilization | Ref |
| HBDH/SWCNT/SPCE; | 3-HB | 0.009 mM | 0.10–2.00 mM | 40 s | 180 | Serum | Physical adsorption | [14] | HBDH/NAD+/SWCNT/SPCE; | 3-HB | 0.009 mM | 0.01–0.10 mM | 40 s | 180 | Serum | Physical adsorption | [15] | 3a-HSD/MWCNTs/OPPF6/NAD+; | Androsterone | 0.15 μM | 0.50–10.00 μM | — | 6 | Serum | Physical adsorption | [16] | PheDH/PAD/rGO/SPCE; | Phenylalanine | 0.20 μM | 1.00–600.00 μM | 60 s | 60 | Blood | Physical adsorption | [17] | GLUD/rGO-Aunano/GCE; | α-KG | 9.20 μM | 66.70–494.50 μM | — | — | Serum | Physical adsorption | [13] | NADH/LDH/Nano-CeO2/GCE; | Lactate | 50.00 μM | 0.20–2.00 mM | <4 s | 12 | Blood | Physical adsorption | [18] | LDH/Au/EVIMC/TiNTs/PANI; | Lactate | 0.165 μM | 0.55–5.50 μM/5.50–3330.00 μM | 8 s | 30 | Serum | Physical adsorption | [19] | PRODH/Fe3O4/MCM-41/nPrNH2/GCE; | L-proline | 0.006 μM | 0.01–0.15 μM | — | — | Blood | Physical adsorption | [11] | LDH/NAD+/pTTCA/MWNTCOOH/gold electrode; | Lactate | 1.00 μM | 5.00–90.00 μM | 10 s | 30 | Serum | Covalent bonding | [20] | Fe3O4/MWNTCOOH/LDH/NAD+/GCE; | Lactate | 5.00 μM | 50.00–500.00 μM | — | — | Serum | Covalent bonding | [21] | FDH/MWNT-COOH/PBA/AuSPE; | HCHO | 6.00 ppb | 10.00 ppb–10.00 ppm | — | 1.25 | Urine | Covalent bonding | [12] | SHL/HBDH/PCS/teflon membrane; | 3-HB | 3.90 μM | 8.00–800.00 μM | 2 s | 20 | Serum | Entrapment | [22] | LDH/rGO-AuNPs/SPCE; | Lactate | 0.13 μM | 0.01–5.00 mM | 8 s | 25 | Serum | Entrapment | [23] | ADH/NAD+/MDB/GMCs/CS/SPCE; | Ethanol | 80.00 μM | 0.50–15.00 mM | 5 s | 40 | Blood | Entrapment | [24] | ADH/MADQUAT/SWCNT-rGO/GCE; | Ethanol | 0.16 μM | 5.00–400.00 μM | — | — | Blood | Entrapment | [25] | URS/GLDH/N-DNW; | Urea | 3.87 mg/dL | 10.00–100.00 mg/dL | 10 s | 30 | Urine | Cross-linking (EDC/NHS) | [26] | GDH/GDI/CS/CNT/GCE; | Glucose | 3.00 μM | 5.00–300.00 μM | 5 s | 8 | Urine | Cross-linking (GA) | [27] | BSS/β-HSD/NHO/Nation/Pt; | Bile acid | — | 2.00–100.00 μM | 5 min | 28 | Urine | Cross-linking (GA) | [28] | ADH/NAD+/MDB/Nation/SPCE; | Ethanol | 11.00 μM | −5.00 mM | 30 s | 30 | Serum | Cross-linking (GA) | [29] | ADH/Ru(bpy)32+/rGO/BSA/GCE; | Ethanol | 0.10 μM | 1.00–2000.00 μM | — | 30 | Serum | Cross-linking (GA) | [30] |
|
|
1-ethyl-3-vinylimidazolium chloride, EVIMC; glutaric dialdehyde, GDI; mobile crystalline material 41, MCM-41; n-propylamine, nPrNH2; octylpyridinium hexafluorophosphate, OPPF6; polyaniline, PANI; and titania nanotubes, TiNTs.
|